Cancer Biomedicine

cancer image

Dr Gabriella Baio - MRI imaging, in vivo cancer imaging

Research interests:

  • Translational cancer imaging research: from the bench to the bedside.
  • Development of new Molecular Imaging biomarkers by Magnetic Resonance Imaging (MRI) and PET/CT to study tumour heterogeneity.
  • New imaging method to study brown adipose tissue and cancer.
  • Fast field cycling MRI.
  • Clinical imaging cancer research in breast, oesophagus and haematological malignancies.

 

Cancer cells - Elaina Collie-Duguid

Dr Elaina Collie-Duguid - Cancer, Biomarkers, Personalised medicine, Cancer stem cells

Dr Collie-Duguid has research interests in the molecular and cellular mechanisms controlling growth of tumours, survival of cancer patients and resistance to chemotherapies, with a particular focus on breast cancer as well as other solid tumours, such as colorectal (bowel), oesophageal (gullet) and lung cancer. Biomarker discovery for prediction of clinical outcomes, including response to therapy, and novel drug target identification are key elements of her translational research programme. Dr Collie-Duguid has extensive experience using microarrays as a tool to enable comprehensive exploration of cancer and other disease relevant genomes.

Imaging tumour hypoxia in cancer patients

Dr Ian Fleming - Positron Emission Tomography (PET) radiotracers, cancer biomarkers, hypoxia, angiogenesis

I am particularly interested in developing novel imaging diagnostics in parallel with targeted therapeutics. My main focus is detecting and treating hypoxic and angiogenic tumours. Current projects include breast, colorectal, oesophageal and pancreatic cancer.

Research interests:

  • Development of novel Positron Emission Tomography (PET) radiotracers to study the biological processes that are characteristic of tumour cells.
  • Development, validation and/or qualification of existing PET radiotracers so that they can be used as predictive, prognostic, pharmacological and/or surrogate response biomarkers in oncology patients.
HeLa cells

Prof. Steven Heys - Role of nutrition in carcinogenesis, mechanisms of chemotherapy resistance in breast cancer, delivery of healthcare to patients with malignant disease

Research interests include the role of nutrition in carcinogenesis, and mechanisms of chemotherapy resistance in breast cancer and delivery of healthcare to patients with malignant disease. This has resulted in the publications of more than 200 peer-reviewed original articles and review papers in these areas. Current research programmes include collaborations both nationally and internationally.

Vascular invasion of a colorectal cancer - Graeme Murray

Prof. Graeme Murray - Tumour biomarker discovery and validation

Research Interests:

  • Diagnostic, predictive and prognostic biomarkers
  • Mechanisms of tumour invasion and metastasis
  • Pathology of gastro-intestinal cancer
Research image - Russell Petty

Prof. Russell Petty - Translational and Clinical Cancer Research

Research Interests:

  • Biomarker and target discovery, qualification and development in oesophageal, gastric, lung and colorectal cancers
  • Development of imaging biomarkers in clinical cancer studies
  • Pathogenesis research in oesophagogastric cancers
  • Clinical cancer research - phase I, II and III therapeutic trials in oesophageal and gastric cancer
18F tracer result - Tim Smith

Dr Tim Smith - Molecular Imaging, radiotracers, nanoparticles, protein labelling

Research Interests:

  • Molecular imaging Preclinical (in-vitro) assessment of novel PET tracers
  • Application of in-vitromodel systems for PET tracer characterisation
  • PET tracer uptake during response to treatment
  • Development of nanoparticle-based 18F-tracers
  • 11C-labelled stilbenes for tumour and neurodegenerative disease imaging
Cancer cells exposed to polyamine linked drugs - Heather Wallace

Prof Heather Wallace - Polyamines, Cancer chemotherapy, Cancer chemoprevention, Selective drug delivery, Apoptosis

Polyamines are found in increased amounts in all cancers where they are necessary for the malignant phenotype. Our lab is focusing on the polyamine pathway for the development of new agents to use against cancers. Our targets are polyamine biosynthesis and breakdown and polyamine transport. We are developing compounds that will use the polyamine transporter to selectively direct novel therapeutics to cancer cells and thus minimise the unwanted side effects of anticancer agents.